Implications of EGFR PharmDx kit for cetuximab eligibility
Christian Ensinger1, William Sterlacci
1Institute of Pathology, Medical University of Innsbruck, A-6020 Innsbruck, Austria. christian.ensinger@i-med.ac.at
Abstract:
EGF receptor (EGFR) represents an attractive target for anticancer therapies in a variety of malignant neoplasms, including colorectal, non-small-cell lung, head and neck carcinomas and gliomas. Monoclonal antibodies, such as cetuximab, are directed against the extracellular EGFR domain, whereas small molecules are targeting the intracellular tyrosine kinase domain. Particularly for application of drugs against extracellular EGFR parts, knowledge about EGFR levels within the cell membrane is of high import, because only EGFR-depending tumors respond to these therapeutic approaches. Immunohistochemical investigation of tissue slides of the primary tumor are performed to screen for EGFR occurrence in tumor cells. Since 2004, the combination of 'EGFR PharmDx kit', a diagnostic test for EGFR, and subsequent application of cetuximab in EGFR-positive colon carcinomas has been approved by the US FDA. It represents the second approved combination of diagnostic tools and dependent application of monoclonal antibody therapies after the successful HercepTest/Herceptin for breast carcinomas. This proceeding represents an important step toward a personalized cancer therapy with major advantages for patients, mainly reduction of toxic side effects and dramatically increased efficiency.
Insights
Epidermal Growth Factor Receptor (EGFR) targeted therapies, like cetuximab, are effective for specific cancers. Immunohistochemistry is crucial for identifying EGFR-positive tumors, enabling personalized cancer treatment and reducing side effects.
Area of Science:
- Oncology
- Molecular Biology
- Immunotherapy
Background:
- Epidermal Growth Factor Receptor (EGFR) is a key target in various cancers, including colorectal, lung, head and neck carcinomas, and gliomas.
- Therapies targeting EGFR include monoclonal antibodies (e.g., cetuximab) against the extracellular domain and small molecules against the intracellular tyrosine kinase domain.
- Accurate assessment of EGFR levels in the cell membrane is critical for predicting patient response to extracellularly acting EGFR therapies.
Purpose of the Study:
- To highlight the importance of determining EGFR levels for effective anticancer therapy.
- To discuss the role of immunohistochemical methods in identifying EGFR-positive tumors.
- To emphasize the significance of diagnostic tools combined with targeted therapies for personalized cancer treatment.
Main Methods:
- Immunohistochemical investigation of primary tumor tissue slides to screen for EGFR expression.
- Utilizing diagnostic kits like the 'EGFR PharmDx kit' for EGFR detection.
Main Results:
- The US FDA approved the combination of the 'EGFR PharmDx kit' and cetuximab for EGFR-positive colon carcinomas in 2004.
- This approval followed the successful HercepTest/Herceptin combination for breast carcinomas, establishing a precedent for diagnostic-guided therapy.
Conclusions:
- The integration of diagnostic tests with targeted monoclonal antibody therapies represents a significant advancement in personalized cancer medicine.
- This approach offers substantial patient benefits, including minimized toxic side effects and enhanced therapeutic efficacy.
- EGFR-targeted therapies, guided by diagnostic screening, are crucial for improving outcomes in specific cancer types.
Related Concept Videos
02:38Mitogens and the Cell Cycle
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase